EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieLeitlinieOpen Access · CC BY-NC-ND 4.0

Implementation of Guideline-Directed Medical Therapy in Patients with Heart Failure with Reduced Ejection Fraction (OpTIMa-HF Registry)

Implementierung leitliniengerechter medikamentöser Therapie bei Patient:innen mit Herzinsuffizienz mit reduzierter Ejektionsfraktion (OpTIMa-HF-Register)

Stefania Paolillo, Christian Basile, Federica Marzano, Dario Bruzzese, Piergiuseppe Agostoni, Irene Mattavelli, Angelo Aloisio, Pietro Ameri, Martina Solimano, Natale Daniele Brunetti, Paolo Calabrò, Arturo Cesaro und 48 weitere

ESC Heart Failure · 01.06.2025 · 12 (3) · 1786-1795

DOI: 10.1002/ehf2.15172 ↗

Auf einen Blick

Im italienischen OPTIMA-HF-Register erhielten die meisten Patient:innen mit HFrEF die vier Leitlinienklassen, aber weniger als die Hälfte die empfohlene Vierfachkombination. Ziel- bzw. ausreichende Dosierungen wurden nur bei einem Teil erreicht.

Fragestellung

Wie häufig wird die leitliniengerechte medikamentöse Therapie bei Patient:innen mit chronischer HFrEF in der Praxis umgesetzt?

Methode

Beobachtende, querschnittliche multizentrische Registerstudie in Italien; T0 mit retrospektiver Datenerhebung bei konsekutiven HF-Patient:innen zwischen Januar und Oktober 2022.

Ergebnisse

29 Zentren mit 2110 HF-Patient:innen, davon 1390 mit HFrEF. 89,1 % erhielten RAASi/ARNI, 95,1 % Betablocker, 75,8 % MRA, 63,2 % SGLT2i; 46,9 % erhielten alle vier Klassen.

Einschränkungen

Nicht in allen Patient:innen ohne Kontraindikationen wurde jede Wirkstoffklasse eingesetzt; Dosisangaben zeigen noch unzureichende Zielerreichung.

Schlussfolgerung der Autor:innen

Die fundamentalen HFrEF-Arzneien wurden bei den meisten italienischen Patient:innen verordnet; <50 % erhielten jedoch eine optimale Kombinationstherapie, und Ziel-Dosen waren noch nicht zufriedenstellend erreicht. Es werden Strategien zur besseren Umsetzung benötigt.

Kernaussagen

  • 46,9 % erhielten alle vier empfohlenen Wirkstoffklassen
  • Hohe Verordnungsraten, aber Lücken trotz fehlender Kontraindikationen
  • Ziel-Dosen von RAASi/ARNI und Betablockern oft nicht erreicht

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Beobachtungsstudie in der Zeitschrift ESC Heart Failure, online erschienen am 05.02.2025. Verfasst von Stefania Paolillo und 59 weiteren Autor:innen. Beteiligte Einrichtung: Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy. Hauptthemen laut MEDLINE: Heart Failure, Stroke Volume, Registries, Practice Guidelines as Topic. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The last released European guidelines on the management of heart failure (HF) recommend in patients with chronic HF with reduced ejection fraction (HFrEF) a pharmacological approach based on four fundamental drugs to be rapidly implemented and then uptitrated to modify disease progression. The aim of the Optimization of Therapy in the Italian Management of Heart Failure (OPTIMA-HF) registry is to collect data on chronic HF outpatients in different settings of care. In the present analysis, we report the first analysis of the OPTIMA-HF registry, focusing on the real-life use of guideline-directed medical therapy in patients affected by HFrEF.

Methods

OPTIMA-HF is an observational, cross-sectional, multicentre, real-life Italian registry conducted in two different clinical settings: HF outpatients' clinics of Italian hospitals and community HF outpatients' services. The study comprises a T0 phase—retrospective data collection, in which data of consecutive HF outpatients seen between January and October 2022 were collected; an educational activity phase; and a T1 phase—prospective data collection, in which data of consecutive HF outpatients seen between September 2023 and November 2023 were collected. In the present analysis, we describe the T0 phase focusing on HFrEF drug prescription rates, types, doses, combination therapy, the presence of contraindications and reasons of non-optimized treatment.

Results

Twenty-nine centres enrolled 2110 HF patients, of which 1390 (65.9%) had HFrEF [69.5 ± 11.9 years, 76.2% males, 4.1 years since HF diagnosis, median ejection fraction (EF) 33%]. Among HFrEF patients, 89.1% were on treatment with renin–angiotensin–aldosterone system inhibitor (RAASi)/angiotensin receptor neprilysin inhibitor (ARNI) (72% ARNI and 17.1% RAASi), 95.1% with beta-blockers, 75.8% with mineralocorticoid receptor antagonists (MRA) and 63.2% with sodium/glucose cotransporter 2 inhibitors (SGLT2i). Despite high prescription rates, a non-negligible number of patients with no contraindications were not treated with each specific drug. Patients taking all four drug classes, as recommended by guidelines, were mere 46.9%. Regarding doses, a still low number of patients on RAASi/ARNI and beta-blockers were treated with a dose ≥50% of the target doses recommended by the European guidelines.

Conclusions

The OPTIMA-HF registry reported that HFrEF fundamental drugs are prescribed in most Italian patients; however, <50% of patients receive optimal combination therapy, and still not a satisfying number of patients receive target doses. Strategies to improve implementation of guideline-directed medical therapy are needed to improve HF prognosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureStroke VolumeRegistriesPractice Guidelines as TopicDisease ManagementHumansMaleCross-Sectional StudiesFemaleAgedItalyRetrospective StudiesMineralocorticoid Receptor AntagonistsMiddle AgedAngiotensin Receptor AntagonistsGuideline Adherence

Stichwörter der Autor:innen

HFrEFdisease‐modifying drugsguideline‐directed medical therapyheart failurepharmacotherapy

Substanzen

Mineralocorticoid Receptor AntagonistsAngiotensin Receptor Antagonists

Autor:innen und Institutionen

  • Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.
  • Department of Public Health, University of Naples Federico II, Naples, Italy.
  • Centro Cardiologico Monzino, IRCCS, Milan, Italy.
  • Cardiovascular Section, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
  • Cardiology Unit, Casa di Cura Villa Verde, Taranto, Italy.
  • IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Zitieren

APA

Paolillo, S., Basile, C., Marzano, F., Bruzzese, D., Agostoni, P., Mattavelli, I., Aloisio, A., Ameri, P., Solimano, M., Brunetti, N. D., Calabrò, P., Cesaro, A., Cameli, M., Mandoli, G. E., Carluccio, E., Belardinelli, C., Carugo, S., Casalino, L., Chiuini, E., …, & Franzese, M. (2025). Implementation of Guideline-Directed Medical Therapy in Patients with Heart Failure with Reduced Ejection Fraction (OpTIMa-HF Registry). ESC Heart Failure, 12(3), 1786-1795. https://doi.org/10.1002/ehf2.15172

Vancouver

Paolillo S, Basile C, Marzano F, Bruzzese D, Agostoni P, Mattavelli I, et al. Implementation of Guideline-Directed Medical Therapy in Patients with Heart Failure with Reduced Ejection Fraction (OpTIMa-HF Registry). ESC Heart Failure. 2025;12(3):1786-1795. doi:10.1002/ehf2.15172

BibTeX
@article{Paolillo2025,
  author = {Paolillo, Stefania and Basile, Christian and Marzano, Federica and Bruzzese, Dario and Agostoni, Piergiuseppe and Mattavelli, Irene and Aloisio, Angelo and Ameri, Pietro and Solimano, Martina and Brunetti, Natale Daniele and Calabrò, Paolo and Cesaro, Arturo and Cameli, Matteo and Mandoli, Giulia Elena and Carluccio, Erberto and Belardinelli, Chiara and Carugo, Stefano and Casalino, Laura and Chiuini, Emilia and Cosmi, Deborah and Dini, Frank Lloyd and Di Santo, Mariafrancesca and Esposito, Gennaro and Ferrara, Ferdinando and Fierro, Maria Francesca and Galasso, Gennaro and Gallo, Luca and Rispoli, Antonella and Gargiulo, Paola and Grigioni, Francesco and Segreti, Andrea and Guarnaccia, Franco and Guarnaccia, Natale and Guerra, Federico and Cicchirillo, Emanuele and Indolfi, Ciro and Larcher, Mauro and Lillo, Adele and Metra, Marco and Montisci, Roberta and Marchetti, Maria Francesca and Nodari, Savina and Fioretti, Francesco and Nardi, Ermanno and Oliviero, Ugo and Palazzuoli, Alberto and Patti, Giuseppe and Pepe, Marco and Pacelli, Filomena and Perrone Filardi, Fabrizio and Putortì, Giuseppe and Santoro, Giosuè and Senni, Michele and D'Elia, Emilia and Severino, Paolo and D'Amato, Andrea and Soriano, Simona and Sinagra, Gianfranco and Rossi, Maddalena and Franzese, Monica},
  title = {Implementation of Guideline-Directed Medical Therapy in Patients with Heart Failure with Reduced Ejection Fraction (OpTIMa-HF Registry)},
  journal = {ESC Heart Failure},
  year = {2025},
  volume = {12},
  number = {3},
  pages = {1786--1795},
  doi = {10.1002/ehf2.15172}
}
Kostenlos starten →